NCT01540500已完成1 期
An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)
研究概览
简要总结
The purpose of this research study is to evaluate whether administration of a CYP1A2 inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites. The safety and tolerability of tasimelteon will also be assessed throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women between 18 - 55 years, inclusive;
- •Non-smokers [abstinence from smoking for at least 6 months before the screening visit] and test negative for cotinine at screening and baseline;
- •Subjects with Body Mass Index (BMI) of ≥18 and ≤35 kg/m2 (BMI = weight (kg)/ [height (m)]2);
- •Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and females must have a negative pregnancy test at the screening and baseline visits;
- •Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.
- •Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:
- •Body temperature between 35.0-37.5 °C;
- •Systolic blood pressure between 90-150 mmHg;
- •Diastolic blood pressure between 50-95 mmHg;
- •Pulse rate between 50-100 bpm.
- •Ability and acceptance to provide written informed consent;
- •Willing and able to comply with study requirements and restrictions;
- •Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, clinical laboratory tests.
排除标准
- •History of recent (within six months) drug or alcohol abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated by the laboratory assays conducted during the Screening Visit or at Baseline;
- •Any major surgery within three months of Baseline or any minor surgery within one month;
- •History or current evidence of cardiovascular, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction judged by the Investigator to be clinically significant;
- •Subjects who are currently considered a suicide risk, any subject who has ever made a suicide attempt, or those who are currently demonstrating active (within the last year) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale (C-SSRS);
- •Any condition requiring the regular use of medication except those listed on Section 8.2;
- •Exposure to any investigational drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of baseline;
- •Anyone who has taken a melatonin preparation chronically within the past two months prior to Day 1;
- •Donation or loss of 400 mL or more of blood within two months prior to the Baseline Visit;
- •Significant illness within the two weeks prior to Baseline;
- •A known intolerance or hypersensitivity to fluvoxamine, tasimelteon or drugs similar to tasimelteon (including melatonin) or fluvoxamine;
- •Pregnant or lactating females;
- •History of liver disease and/or positive for one or more of the following serological results:
- •A positive hepatitis C antibody test (anti-HCV)
- •A positive hepatitis B surface antigen (HBsAg)
- •A positive HIV test result
- •Exposure (within 2 weeks of the Baseline Visit) of any over-the-counter medications including dietary supplements and/or herbal remedies, except those listed on Section 8.2;
- •Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 days preceding the Screening visit;
- •Participation in a previous BMS-214778/VEC-162 trial;
- •Use of any food or beverage containing grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats for at least 2 weeks before the Baseline Visit until the end of the study;
- •Inability to be venipunctured and/or tolerate venous access;
- •Subjects who are unable to read or speak English;
- •Any other sound medical reason as determined by the clinical Investigator.
研究组 & 干预措施
Steady State PK Group
Experimental
干预措施: Tasimelteon (Drug)
Steady State PK Group
Experimental
干预措施: Fluvoxamine (Drug)
结局指标
主要结局
Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)
时间窗: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12 and 24 hours post-dose.
次要结局
- Fluvoxamine pharmacokinetic parameters (AUC, Cmax, Tmax)(Pre-dose, 1, 3, 4, 6, 8, 12, and 24 hours post-dose)
- The Columbia Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation.(Screening, Day -1 (baseline), and Day 9 (end of study))
- Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M9, M11, M12, M13, and M14(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12 and 24 hours post-dose.)
- Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signs(Days 1-9)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor MalignanciesSolid Tumor MalignanciesNCT01290380Novartis Pharmaceuticals54
已完成
不适用
Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of TheophyllineChronic Obstructive Pulmonary DiseaseNCT03015090XiaoGuang Zou110
已完成
1 期
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464HealthyNCT05121714Abivax S.A.59
已完成
1 期
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)Healthy VolunteersNCT05532358MODAG GmbH54
已完成
不适用
Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of TheophyllineChronic Obstructive Pulmonary DiseaseNCT02001935Zhujiang Hospital102